Tobramycin

Description

Tobramycin ophthalmic solution USP, 0.3% is a sterile topical ophthalmic antibiotic formulation designed for the treatment of external ophthalmic infections. Each milliliter of the solution contains 0.3% tobramycin (3 mg) as the active ingredient, along with 0.01% benzalkonium chloride (0.1 mg) as a preservative. The formulation includes inactive ingredients such as boric acid, sodium sulfate decahydrate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (for pH adjustment), and water for injection.

The pH of the solution ranges from 7.0 to 8.0, with an osmolality of 260-320 mOsm/kg. Tobramycin, a water-soluble aminoglycoside antibiotic, exhibits activity against a broad spectrum of gram-negative and gram-positive ophthalmic pathogens. The molecular weight of tobramycin is 467.52, and its chemical formula is C₁₈H₃₇N₅O₉. The chemical name is O-3-Amino-3-deoxy-α-D-glucopyranosyl-(1→4)-O-2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1→6)-2-deoxy-L-streptamine.

Uses and Indications

Tobramycin ophthalmic solution 0.3% is indicated for the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. This topical antibiotic is effective in managing bacterial infections in the ocular region.

Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution 0.3%.

Clinical studies have demonstrated that tobramycin is safe and effective for use in pediatric patients.

Dosage and Administration

In cases of mild to moderate disease, the recommended dosage is to instill 1 or 2 drops into the affected eye(s) every 4 hours. For severe infections, the dosage is increased to 2 drops instilled into the eye(s) hourly until clinical improvement is observed. Following improvement, the frequency of administration should be gradually reduced before discontinuation of treatment.

Contraindications

Tobramycin ophthalmic solution 0.3% is contraindicated in patients with a known hypersensitivity to any of its components. Use in these patients may lead to severe allergic reactions.

Warnings and Precautions

Topical ophthalmic use is the only approved route for administration of this medication; it is strictly contraindicated for injection into the eye. Healthcare professionals should be aware that some patients may exhibit sensitivity to topically applied aminoglycosides, which can lead to a range of hypersensitivity reactions.

The severity of these reactions can vary significantly, manifesting as localized effects or more generalized symptoms. Patients may experience erythema, itching, urticaria, skin rash, or in severe cases, anaphylaxis, anaphylactoid reactions, or bullous reactions. In the event that a patient develops a sensitivity reaction to tobramycin ophthalmic solution 0.3%, it is imperative to discontinue use immediately to prevent further complications.

Healthcare providers are advised to monitor patients closely for any signs of hypersensitivity during treatment and to educate them on the potential symptoms to watch for.

Side Effects

Patients receiving tobramycin ophthalmic solution may experience adverse reactions, which can be categorized by frequency and seriousness.

The most frequent adverse reactions observed include hypersensitivity and localized ocular toxicity. Localized ocular toxicity may manifest as lid itching, swelling, and conjunctival erythema, occurring in less than three out of 100 patients treated with the solution.

In addition to these common reactions, postmarketing experience has revealed more serious adverse events, including anaphylactic reactions, Stevens-Johnson syndrome, and erythema multiforme. The severity of hypersensitivity reactions can vary significantly, ranging from localized effects to more generalized reactions such as erythema, itching, urticaria, skin rash, and in severe cases, anaphylaxis or anaphylactoid reactions. It is advised that if a sensitivity reaction occurs, the use of tobramycin ophthalmic solution should be discontinued.

Furthermore, additional adverse reactions associated with systemic aminoglycosides may also be relevant. These include neurotoxicity, ototoxicity, and nephrotoxicity. It is important to note that tobramycin may exacerbate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis and Parkinson’s disease.

Patients should be monitored for these adverse reactions, and appropriate measures should be taken if any serious reactions are observed.

Drug Interactions

Tobramycin ophthalmic solution is associated with several important drug interactions that warrant consideration.

Hypersensitivity Reactions Patients with a known sensitivity to aminoglycosides may experience hypersensitivity reactions when using tobramycin ophthalmic solution. In such cases, it is advised to discontinue the use of the product and initiate appropriate therapeutic measures.

Cross-Sensitivity There is a potential for cross-sensitivity to other aminoglycoside antibiotics. If a hypersensitivity reaction occurs with tobramycin, it is recommended to avoid the use of other aminoglycosides.

Neuromuscular Effects Aminoglycosides, including tobramycin, may exacerbate muscle weakness in individuals with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease. Clinicians should monitor patients with these conditions closely due to the potential impact on neuromuscular function.

Packaging & NDC

The table below lists all NDC Code configurations of Tobramycin, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 2 months have not been established. Clinical studies have demonstrated that tobramycin is safe and effective for use in children.

Geriatric Use

Elderly patients, defined as those aged 65 years and older, have not demonstrated any overall differences in safety or effectiveness compared to younger patients. Therefore, no specific dosage adjustments are necessary for this population. However, healthcare providers should remain vigilant in monitoring geriatric patients for any potential age-related changes that may influence individual responses to treatment. It is essential to consider the overall health status and comorbidities of elderly patients when prescribing, as these factors may impact the therapeutic outcomes and safety profile.

Pregnancy

Reproduction studies in three types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. However, there are no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, tobramycin should be used during pregnancy only if clearly needed. Healthcare professionals are advised to weigh the potential benefits against the risks when considering the use of this drug in pregnant patients.

Lactation

Because of the potential for adverse reactions in nursing infants from tobramycin ophthalmic solution, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, specific antidotes or treatments may be indicated based on the substance involved in the overdose. Consultation with a poison control center or a medical toxicologist is recommended to guide the management of the patient and to determine the most appropriate interventions.

Overall, vigilance and prompt action are critical in managing cases of suspected overdose, even in the absence of detailed information regarding specific overdosage effects.

Nonclinical Toxicology

Reproduction studies conducted in three animal species at doses up to 33 times the normal human systemic dose have demonstrated no evidence of impaired fertility or teratogenic effects associated with tobramycin. However, it is important to note that there are no adequate and well-controlled studies in pregnant women. Given that animal studies may not always accurately predict human responses, the use of this drug during pregnancy should be considered only when clearly necessary.

Postmarketing Experience

Postmarketing experience has identified additional adverse reactions associated with the use of the product. Reports include anaphylactic reactions, Stevens-Johnson syndrome, and erythema multiforme.

Furthermore, systemic aminoglycosides have been associated with neurotoxicity, ototoxicity, and nephrotoxicity in patients undergoing treatment. It has also been noted that aminoglycosides may exacerbate muscle weakness in individuals with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, due to their potential impact on neuromuscular function.

Patient Counseling

Patients should be advised not to wear contact lenses if they exhibit any signs or symptoms of a bacterial ocular infection. Healthcare providers should emphasize the importance of maintaining proper hygiene when using the medication, specifically instructing patients not to touch the dropper tip to any surface, as this may lead to contamination of the solution.

In the event that a patient experiences a sensitivity reaction to tobramycin ophthalmic solution 0.3%, they should be instructed to discontinue use immediately and consult their healthcare provider.

For nursing mothers, it is crucial to discuss the potential risks associated with tobramycin ophthalmic solution, as adverse reactions may occur in nursing infants. A careful decision should be made regarding whether to discontinue nursing or the medication, weighing the importance of the drug to the mother against the potential risks to the infant.

Additionally, healthcare providers should inform patients that the safety and effectiveness of this medication have not been established in pediatric patients under the age of 2 months, and caution should be exercised when prescribing to this population.

Storage and Handling

Tobramycin Ophthalmic Solution, USP 0.3% is supplied in a suitable container that ensures product integrity. It should be stored at a temperature range of 2°C to 25°C (36°F to 77°F) to maintain its efficacy.

Once opened, the solution can be used until the expiration date indicated on the bottle. It is important to handle the product with care to prevent contamination and ensure safe usage.

Additional Clinical Information

Patients should instill 1 or 2 drops into the affected eye(s) every 4 hours for mild to moderate disease. In cases of severe infections, the recommended dosage is 2 drops into the eye(s) hourly until improvement is observed, after which the frequency should be reduced prior to discontinuation. Clinicians should counsel patients to avoid touching the dropper tip to any surface to prevent contamination of the solution. Additionally, patients exhibiting signs and symptoms of bacterial ocular infection should refrain from wearing contact lenses.

Postmarketing experience has revealed additional adverse reactions, including anaphylactic reactions, Stevens-Johnson syndrome, and erythema multiforme. There have also been reports of neurotoxicity, ototoxicity, and nephrotoxicity in patients undergoing systemic aminoglycoside therapy. It is important to note that aminoglycosides may exacerbate muscle weakness in individuals with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, due to their potential impact on neuromuscular function.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Tobramycin as submitted by Gland Pharma Limited. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)